The phase II RESOLVE-Lung trial evaluated namilumab in people with active pulmonary sarcoidosis. The trial included 107 participants. Namilumab did not provide a clinical benefit compared with placebo; a key outcome related to the need for additional treatment occurred in 37.5% of participants in the namilumab group and 23.5% in the placebo group.
The result does not support the use of namilumab as a treatment for sarcoidosis. This is an investigational drug, not an approved treatment recommendation. The trial was of moderate size, so further research is needed to understand outcomes in specific subgroups.
Source type: randomized phase II trial (RESOLVE-Lung).
Source: https://pubmed.ncbi.nlm.nih.gov/41819539/
Add comment
Comments